Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28710888 | 0.81 | MEN1 (0.50) | KMT2AMEN1SMN1; SMN2HPGDNPSR1 | |
| SCHEMBL3341865 | 0.79 | MEN1 (0.48) | KMT2AMEN1SMN1; SMN2HPGDNPSR1 | |
| SCHEMBL10723840 | 0.77 | NPSR1 (0.37) | KMT2AMEN1SMN1; SMN2HPGDNPSR1 | |
| SCHEMBL9592601 | 0.76 | MEN1 (0.40) | KMT2AMEN1SMN1; SMN2HPGDNPSR1 | |
| SCHEMBL11941449 | 0.75 | MEN1 (0.46) | KMT2AMEN1NPSR1LMNAALDH1A1 | |
| SCHEMBL11941497 | 0.75 | MEN1 (0.46) | KMT2AMEN1NPSR1LMNAALDH1A1 | |
| SCHEMBL6005836 | 0.75 | CYP3A4 (0.48) | KMT2AMEN1SMN1; SMN2HPGDNPSR1 | |
| SCHEMBL11019559 | 0.75 | LMNA (0.51) | KMT2AMEN1SMN1; SMN2HPGDNPSR1 | |
| SCHEMBL28857096 | 0.73 | MEN1 (0.48) | KMT2AMEN1SMN1; SMN2HPGDNPSR1 | |
| SCHEMBL1136246 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2867225-B1 | PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS | NOVARTIS AG (CH) | 2017-08-09 | — | — | EP | disclosed |
| US-9468661-B2 | Pyrrolidine derivatives and their use as complement pathway modulators | NOVARTIS AG (CH) | 2016-10-18 | — | — | US | disclosed |
| US-20150190457-A1 | PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS | NOVARTIS AG (CH) | 2015-07-09 | — | — | US | disclosed |
| EP-2867225-A1 | PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS | Novartis AG (CH) | 2015-05-06 | — | — | EP | disclosed |
| WO-2014002054-A1 | PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS | NOVARTIS AG (CH) | 2014-01-03 | — | — | WO | disclosed |
| US-4728743-A | Process for the production of 3-oxonitriles | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1988-03-01 | — | — | US | disclosed |
| US-4716237-A | Process for the production of 3-oxonitriles | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1987-12-29 | — | — | US | disclosed |
| US-4390719-A | 1-Methyl-2-chlorocyclopropanecarboxylic acid and its ester | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1983-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150190457-A1 | PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS | C5, C9, TFPI | KMT2A 4701/4885MEN1 1750/4885SMN1; SMN2 4539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.